SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following the announcement of a private debt exchange that will reduce long-term obligations by converting notes into equity, a move that has sparked intense debate among retail investors regarding potential dilution versus long-term balance sheet strengthening. The community remains deeply divided, with some users speculating the move is a strategic precursor to a major acquisition, while others express frustration over management's capital allocation and the impact on share value.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble is trending as investors bet on a potential short squeeze fueled by an exceptionally high short interest relative to the float and bullish sentiment surrounding the company's expansion into AI infrastructure through its acquisition of Northern Data. The community is intensely debating the stock's valuation as a data center and compute-heavy AI play while tracking upcoming earnings and the potential impact of strategic partnerships on the firm's cloud revenue.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The S&P 500 is surging toward all-time highs as a massive short squeeze unfolds, fueled by market optimism surrounding potential diplomatic talks with Iran and coordinated currency interventions. Community members are actively debating the sustainability of this aggressive melt-up, with many traders questioning the validity of the underlying news catalysts while bulls remain focused on the strength of recent momentum.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is attracting significant attention as investors react to a combination of strong commercial momentum for its MS franchise and persistent short interest, fueling active community debate regarding a potential buyout or long-term valuation expansion. Despite volatility, proponents remain focused on the companys upcoming subcutaneous program and potential label expansions in secondary indications as key catalysts for future growth.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is facing intense investor speculation as the community eagerly anticipates Phase 3 IZAR-1 trial results, with sentiment split between confidence in 'best-in-class' outcomes and frustration over the delayed timeline. Active discussions focus on interpreting management's 'about a month' guidance, the potential for a transformative partnership or buyout, and the impact of heavy institutional ownership on current price volatility.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is facing significant downward pressure and setting new lows as the market rotates out of high-growth names, leading the community to debate whether current prices represent a generational buying opportunity or a deeper fundamental decline. Investors remain sharply divided, with bulls pointing to historical buyback potential and strong brand momentum while bears cite increasing competitive headwinds and margin pressures ahead of the upcoming earnings release.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending as investors react to the FAA's certification of the 737 MAX-7, a long-awaited milestone that serves as a key catalyst for potential delivery momentum and cash flow recovery. The community is actively debating whether this certification signals a sustained turnaround for the companys broader aircraft backlog or if the stock will continue to face volatility from ongoing execution challenges and defense-related cost pressures.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is currently trending as investors brace for the upcoming earnings call, with community sentiment deeply polarized between frustration over stagnant share price performance and optimism surrounding the potential for proprietary Matrix-M licensing deals. The discussion is heavily focused on the company's strategic pivot toward a leaner licensing model, with many participants intensely scrutinizing management's communication and the long-term value of their combination vaccine pipeline.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony Corp (UAMY) is trending as retail investors rally behind the stock, viewing recent federal executive orders and defense-related supply chain mandates as major catalysts for the critical minerals sector. While community members debate whether current price action is being driven by institutional manipulation or a fundamental turnaround in defense demand, many are actively discussing the stock's role as a sole-source domestic provider for military-grade antimony.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending due to a surge in positive sentiment following recent record-breaking ABS deal closures and signals of improved profitability. Community discourse focuses on the stock's significant discount relative to fintech peers, with investors actively discussing potential analyst price target upgrades and a possible short squeeze as the company approaches its upcoming earnings report.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Missed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lower 

Equity

Drugmakers have announced 37 biotech acquisitions worth at least $1 billion this year, topping the previous annual record.

BioCryst Pharmaceuticals Appoints David Jenkins As Chief Scientific Officer

(RTTNews) - BioCryst Pharmaceuticals, Inc. (BCRX) said on Wednesday that it has appointed David W. Jenkins to the newly created role of Chief Scientific Officer with immediate effect...

Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet

The consensus price target hints at an 118% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs?

Penguin Solutions, Arista Networks, and Biocryst Pharmaceuticals surged to 52-week highs on Wednesday amid a rotation into technology and healthcare stocks. 

BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?

BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

VKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal?

Wall Street sees bigger upside in VKTX, with Koyfin’s average target implying 120% upside versus 99% for BCRX.

Why Did CRNX, D, BCRX Stocks Surge To 52-Week Highs Today? 

Investors favored companies benefiting from biotech deals, rising power demand from AI data centers, and cost-cutting efforts to improve profits. 


Ono Pharmaceutical Co. (OPHLF) Moves 10.4% Higher: Will This Strength Last?

Ono Pharmaceutical Co. (OPHLF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

BCRX Stock Set For Best Week In Over 3 Months – Retail Shifts Focus To This Crucial Breakout Level

BCRX stock climbed past its key resistance at $10.32 to hit a record high earlier in the session, before paring most of the gains.

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings

BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, reaffirmed FY2026 sales guidance, and received positive price target changes from analysts.read more...

$BCRX Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of -$2.98
• Reported revenue of $156.41M up 7.48% YoY
• BioCryst maintained its full year 2026 global net ORLADEYO revenue guidance of $625M to $645M and total revenue of $635M to $660M, with non-GAAP operating expenses between $450M and $470M.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

BCRXBiocryst Pharmaceuticals Inc.

Fundamentals

Connect Stocktwits to ChatGPT

Latest BCRX News